---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Drug interactions questions"
description: "Drug interactions questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Enhertu have drug interactions? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/enhertu/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Drug interactions questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Drug interactions

<a id="enhertu-drug-interactions"></a>

### Does Enhertu have drug interactions?

> “Drug interaction studies<sup>1</sup>
> Effect of CYP3A and OATP inhibitors on DXd (clinical studies): There were no clinically meaningful drug-drug interactions between ENHERTU and itraconazole (CYP3A inhibitor), as well as ritonavir (OATP1B/CYP3A inhibitor)
> Effect of DXd on CYP enzymes (in vitro studies): DXd did not inhibit common CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A) nor induce CYP1A2, CYP2B6, or CYP3A
> Effect of DXd on UGT enzymes (in vitro studies): DXd is not a substrate of UGT
> Effect of DXd on transporters (in vitro studies): DXd is not an inhibitor of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, P-gp, BCRP, or BSEP
> DXd is a substrate of OATP1B1, OATP1B3, MATE2-K, P-gp, MRP1, and BCRP”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Drug%20interaction,MATE2%2DK%2C%20P%2Dgp%2C%20MRP1%2C%20and%20BCRP)

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/enhertu/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/enhertu/safety)
- [Specific populations](https://www.evicenter.com/medical-information/enhertu/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines)
